Related Experiment Video
Updated: May 1, 2026
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
15.2K
Accelerated radiotherapy for T1 to T2 glottic cancer
Atsushi Motegi1, Mitsuhiko Kawashima, Satoko Arahira
1Division of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Head & Neck
|March 29, 2014
Summary
Accelerated radiotherapy (RT) shows promise for early glottic cancer, improving local control rates. This treatment approach is feasible and well-tolerated, offering encouraging survival outcomes for patients.
Area of Science:
- Oncology
- Radiation Oncology
- Head and Neck Cancer
Background:
- Glottic cancer presents a significant challenge in head and neck oncology.
- Optimizing radiotherapy fractionation is crucial for improving treatment outcomes.
- Previous treatments have varying success rates for T1/T2 N0 glottic cancer.
Purpose of the Study:
- To evaluate the efficacy of accelerated fractionation radiotherapy (RT) in patients with early-stage glottic cancer (T1/T2 N0).
- To assess local control rates and overall survival (OS) following accelerated RT.
- To determine the toxicity profile of this accelerated RT regimen.
Main Methods:
- Retrospective review of medical charts for 148 consecutive patients treated with RT.
- Utilized a once-daily fractionation schedule of 2.4 Gray (Gy).
- Doses varied between 60 Gy/25 fractions for T1 disease and 64.8 Gy/27 fractions for T2 disease or specific T1 subgroups.
Main Results:
- High 5-year local control rates: 93% for T1 disease and 77% for T2 disease.
- Excellent 5-year overall survival (OS) rates: 96% for T1 and 91% for T2.
- Low toxicity: No severe acute toxicities observed; 1% developed severe late toxicity.
Conclusions:
- Accelerated RT is a feasible and effective treatment for early glottic cancer.
- The regimen demonstrates encouraging local control and survival rates.
- The treatment is associated with a favorable toxicity profile.
